| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 04/18/2002 | WO2002030957A1 Peptide-based gemini surfactant compounds facilitating the transfer into cells |
| 04/18/2002 | WO2002030471A2 A novel system for the evaluation of the activity and/or specificity of a viral component |
| 04/18/2002 | WO2002030470A1 Methods and compositions for nucleic acid delivery |
| 04/18/2002 | WO2002030468A1 Complexes for transferring nucleic acids into cells |
| 04/18/2002 | WO2002030465A2 Compositions that inhibit proliferation of cancer cells |
| 04/18/2002 | WO2002030464A1 Novel drugs for liver diseases |
| 04/18/2002 | WO2002030462A2 Hedgehog antagonists, methods and uses related thereto |
| 04/18/2002 | WO2002030461A2 Methods for treating disorders of the female reproductive system |
| 04/18/2002 | WO2002030455A2 Agents for the treatment of viral infections |
| 04/18/2002 | WO2002030435A1 Treatment of t cell disorders |
| 04/18/2002 | WO2002030351A2 Improvement of graft acceptance through manipulation of thymic regeneration |
| 04/18/2002 | WO2002030320A2 Stimulation of thymus for vaccination development |
| 04/18/2002 | WO2002030257A2 Normalization of defective t cell responsiveness through manipulation of thymic regeneration |
| 04/18/2002 | WO2002030206A1 Genetically altered mammalian embryonic stem cells, their living progeny, and their therapeutic application for improving cardiac function after myocardial infarction |
| 04/18/2002 | WO2002030184A1 Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of socs sequence in the animal |
| 04/18/2002 | WO2002017968A3 Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain-2 |
| 04/18/2002 | WO2002000914A3 Bioengineered vehicles for targeted nucleic acid delivery |
| 04/18/2002 | WO2002000248A3 Use of urokinase inhibitors for the treatment and/or prevention of pulmonary hypertension and/or cardiac remodelling |
| 04/18/2002 | WO2001093902A3 Immunostimulatory rna/dna hybrid molecules |
| 04/18/2002 | WO2001088141A3 Synthetic gagpol genes and their uses |
| 04/18/2002 | WO2001081574A3 Regulation of nf-at interacting protein nip 45 variant |
| 04/18/2002 | WO2001077357A3 Chromosomal vectors and uses thereof |
| 04/18/2002 | WO2001070247A3 Salmonella vaccine materials and methods |
| 04/18/2002 | WO2001068912A3 Diagnosis of diseases associated with tumor suppressor genes and oncogenes |
| 04/18/2002 | WO2001066699A3 P27 and p21 in gene therapies |
| 04/18/2002 | WO2001066595A3 Human fgf-23 gene and gene expression products |
| 04/18/2002 | WO2001064876A3 Human schizophrenia gene |
| 04/18/2002 | WO2001064856A3 Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding |
| 04/18/2002 | WO2001062893A3 Compounds and methods for diagnosis and immunotherapy of tuberculosis |
| 04/18/2002 | WO2001060400A3 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease |
| 04/18/2002 | WO2001060377A3 Methods for treatment of lysosomal storage diseases using biphosphonates |
| 04/18/2002 | WO2001059087A3 Compositions for transfecting nucleic acids and their use |
| 04/18/2002 | WO2001058916A3 Antibodies to ccr5 |
| 04/18/2002 | WO2001058483A3 METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES |
| 04/18/2002 | WO2001057257A3 Isolation and identification of mrnas correlating to secreted proteins |
| 04/18/2002 | WO2001051631A3 Regulatory sequence for the specific expression in dendritic cells and uses thereof |
| 04/18/2002 | WO2001040271A3 Cancer associated antigens and uses therefor |
| 04/18/2002 | WO2001025437A3 Growth factor polypeptides and nucleic acids encoding same |
| 04/18/2002 | WO2001024832A3 Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof |
| 04/18/2002 | WO2000073482A9 Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
| 04/18/2002 | WO2000070341A9 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer |
| 04/18/2002 | WO2000069454A9 Suppression of endogenous igfbp-2 to inhibit cancer |
| 04/18/2002 | WO2000055192A3 Hemocyanin and nucleic acid sequence coding for the same |
| 04/18/2002 | US20020045594 Polynucleotide vaccine formulations |
| 04/18/2002 | US20020045593 Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons |
| 04/18/2002 | US20020045591 For gene therapy including polynucleotide sequences encoding peptides including beta-catenin binding domains such as cadherins, for treating cancers with abnormally high levels of beta-catenin |
| 04/18/2002 | US20020045589 Hirulogs are a group of synthetic thrombin-specific inhibitors which conserve the major active sites of hirudin; treatment of vascular restenosis |
| 04/18/2002 | US20020045587 Attenuated bacteria transformed with a promoter activated in cytosol of a host cell to produce a polypeptide lethal to the bacterium, and a host cell compatible promoter coding for therapeutic polypeptide such as an antigen; vaccination |
| 04/18/2002 | US20020045577 Human schizophrenia gene |
| 04/18/2002 | US20020045264 Expression vectors for use in gene therapy |
| 04/18/2002 | US20020045263 Biodegradable particles for use in time release agents and gene therapy |
| 04/18/2002 | US20020045250 Generating adenovirus associated viral plasmid; obtain cell, incubate with helper virus, generate recombinant viral particle, recover plasmid |
| 04/18/2002 | US20020045248 Intracellular inhibitors of gq protein signaling |
| 04/18/2002 | US20020045213 IL-17 receptor like molecules and uses thereof |
| 04/18/2002 | US20020045206 Contacting the cells with a trophic amount of a ptc therapeutic for promoting survival of substantia nigra neuronal cells |
| 04/18/2002 | US20020045202 Enzymatic polypeptide for use in diagnosis, prevention and treatment of inflammatory defects, cancer, diabetes |
| 04/18/2002 | US20020045191 Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
| 04/18/2002 | US20020045165 Detecting target nucleotide sequences in sample; obtain sample, incubate sample with preferential nucleotides, detect bound sequences, classify sample |
| 04/18/2002 | US20020044958 Disaccharide protector; frozen; preserved for longer than one year; shows excellent restoration ability in water |
| 04/18/2002 | US20020044950 Recombinant toxin fragments |
| 04/18/2002 | US20020044941 Nucleic acids, proteins and antibodies |
| 04/18/2002 | US20020044937 Where the protein binds to T-cell cell surface protein, and that complex with nucleic acids, for transporting nucleic acids into human or animal cells which express the T-cell surface protein; antisense therapy, HIV therapy |
| 04/18/2002 | US20020044928 Immunization of dairy cattle with chimeric GapC protein against streptococcus infection |
| 04/18/2002 | US20020044925 Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities |
| 04/18/2002 | US20020044923 Modulating immune responses using antigen presenting human mesenchymal stem cells to induce specific T cell anergy |
| 04/18/2002 | DE10049010A1 Transferrin-Polykation/DNS-Komplexe für die systemische Therapie von Tumorerkrankungen mit zytotoxischen Proteinen Transferrin-polycation / DNA complexes for systemic therapy of tumors with cytotoxic proteins |
| 04/18/2002 | DE10046913A1 Expressionssystem für funktionale Nukleinsäuren Expression system for functional nucleic acids |
| 04/18/2002 | DE10044384A1 Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung Host cells for the packaging of recombinant adeno-associated virus (rAAV), processes for their preparation and their use |
| 04/18/2002 | CA2462671A1 Normalization of defective t cell responsiveness through manipulation of thymic regeneration |
| 04/18/2002 | CA2462073A1 Hematopoietic stem cell gene therapy |
| 04/18/2002 | CA2462046A1 Improvement of graft acceptance through manipulation of thymic regeneration |
| 04/18/2002 | CA2462027A1 Stimulation of thymus for vaccination development |
| 04/18/2002 | CA2425835A1 Methods and compositions for nucleic acid delivery |
| 04/18/2002 | CA2425815A1 Treatment of t cell disorders |
| 04/18/2002 | CA2425779A1 Compositions that inhibit proliferation of cancer cells |
| 04/18/2002 | CA2425767A1 Lipocalins |
| 04/18/2002 | CA2425765A1 Novel drugs for liver diseases |
| 04/18/2002 | CA2425632A1 Agents for the treatment of viral infections |
| 04/18/2002 | CA2425610A1 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 04/18/2002 | CA2425486A1 Flea peritrophin nucleic acid molecules, proteins and uses thereof |
| 04/18/2002 | CA2425407A1 Protecting therapeutic compositions from host-mediated inactivation |
| 04/18/2002 | CA2425356A1 Hedgehog antagonists, methods and uses related thereto |
| 04/18/2002 | CA2425293A1 A novel system for the evaluation of the activity and/or specificity of a viral component |
| 04/18/2002 | CA2425194A1 Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of socs sequence in the animal |
| 04/18/2002 | CA2424992A1 Paramyxovirus vectors for introducing foreign genes into skeletal muscle |
| 04/18/2002 | CA2424987A1 Methods of agonizing and antagonizing fabk |
| 04/18/2002 | CA2424967A1 Complexes for transferring nucleic acids into cells |
| 04/18/2002 | CA2424317A1 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products |
| 04/17/2002 | EP1197550A2 Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| 04/17/2002 | EP1197496A1 Novel peptides |
| 04/17/2002 | EP1197495A2 DNA-binding protein YB-1-containing collagen accumulation inhibitors |
| 04/17/2002 | EP1197220A2 Therapeutic methods and compositions based on delta proteins and nucleic acids |
| 04/17/2002 | EP1196773A1 E4orf4 and pp2a polypeptides, modulators, and mimetics for selectively inducing cell death |
| 04/17/2002 | EP1196638A1 USE OF THE i KRIT1 /i GENE IN ANGIOGENESIS |
| 04/17/2002 | EP1196635A2 Cell death related drug targets in yeast and fungi |
| 04/17/2002 | EP1196618A2 Novel vector complexes and their use in gene therapy |
| 04/17/2002 | EP1196616A2 Replication-competent anti-cancer vectors |
| 04/17/2002 | EP1196612A2 Dna binding protein and sequence as insulators having specific enhancer blocking activity for regulation of gene expression |
| 04/17/2002 | EP1196608A2 Novel antifungal agents and fungicides, method for the production thereof and their use |
| 04/17/2002 | EP1196600A1 Drosophila recombination-associated protein and methods for use |